Myra Vision has announced that a first in-human study has begun for its glaucoma drainage device, the Calibreye system. The Calibreye shunt has titratable outflow control designed to achieve optimal IOP reduction for moderate to severe glaucoma patients, the company’s news release stated. The open-label feasibility study will evaluate the clinical procedure, safety, and overall performance of the device.

“Unlike other glaucoma drainage devices, the titratable outflow of the Calibreye system has the potential to achieve personalized optimal IOP in our patients, with simple, in-office adjustments,” said Rohit Varma, MD, founding director of Southern California Eye Institute in Los Angeles.

“The Calibreye System was implanted using a familiar and established technique," said Ike K. Ahmed, MD, director of the Alan S. Crandall Center for Glaucoma Innovation at the John A. Moran Eye Center and director of the Glaucoma & Advanced Anterior Segment Surgery Fellowship at the University of Toronto, who implanted one of the first devices. "I look forward to following these patients to observe the performance of the implant and the ability to adjust outflow, if needed, over time.”